No

Antihistamine

Treatment of perennial and seasonal allergic rhinitis and chronic urticaria

B

Hypersensitivity to azatadine or to other related antihistamines including cyproheptadine; patients taking monoamine oxidase inhibitors should not use azatadine

Sedation and somnolence are the most commonly reported adverse effects

>10%:

Central nervous system: Slight to moderate drowsiness

Respiratory: Thickening of bronchial secretions

1% to 10%:

Central nervous system: Headache, fatigue, nervousness, dizziness

Gastrointestinal: Appetite increase, weight gain, nausea, diarrhea, abdominal pain, xerostomia

Neuromuscular & skeletal: Arthralgia

Respiratory: Pharyngitis

<1%: Palpitations, edema, depression, angioedema, photosensitivity, rash, hepatitis, myalgia, paresthesia, bronchospasm, epistaxis

Symptoms of overdose include CNS depression or stimulation, dry mouth, flushed skin, fixed and dilated pupils, apnea.

There is no specific treatment for an antihistamine overdose, however, most of its clinical toxicity is due to anticholinergic effects. Anticholinesterase inhibitors may be useful by reducing acetylcholinesterase; anticholinesterase inhibitors include physostigmine, neostigmine, pyridostigmine, and edrophonium. For anticholinergic overdose with severe life-threatening symptoms, physostigmine 1-2 mg (0.5 mg or 0.02 mg/kg for children) I.V., slowly may be given to reverse these effects.

Increased effect/toxicity: Procarbazine, CNS depressants, tricyclic antidepressants, alcohol

Azatadine is a piperidine-derivative antihistamine; has both anticholinergic and antiserotonin activity; has been demonstrated to inhibit mediator release from human mast cells in vitro; mechanism of this action is suggested to prevent calcium entry into the mast cell through voltage-dependent calcium channels

Onset of effect: 1-2 hours

Absorption: Oral: Rapid and extensive

Half-life, elimination: ~8.7 hours

Elimination: ~20% of dose excreted unchanged in urine over 48 hours

Children >12 years and Adults: Oral: 1-2 mg twice daily

Alcohol: Additive CNS effects, avoid use

Drowsiness is common; rare reports of depression

Contraindicated with MAOIs; may produce additive CNS depressant effect with concurrent psychotropic use

No information available to require special precautions

This drug has atropine-like effects and the patient may experience drowsiness; dry mouth, nose, and throat

Take as directed; do not exceed recommended dose. Avoid use of other depressants, alcohol, or sleep-inducing medications unless approved by prescriber. You may experience drowsiness or dizziness (use caution when driving or engaging in tasks requiring alertness until response to drug is known); or dry mouth, abdominal pain, or nausea (frequent small meals, frequent mouth care, chewing gum, or sucking hard candy may help). Report persistent sore throat, difficulty breathing, or expectorating (thick secretions); excessive sedation or mental stimulation; frequent nosebleeds; unusual joint or muscle pain; or lack of improvement or worsening or condition. Breast-feeding precautions: Breast-feeding is not recommended.

Assist with ambulation

Tablet, as maleate: 1 mg

Joske DJ, "Dystonic Reaction to Azatadine," Med J Aust, 1984, 141(7):449.